These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35360663)

  • 21. Ceftaroline Fosamil for the Treatment of
    Vazquez JA; Maggiore CR; Cole P; Smith A; Jandourek A; Friedland HD
    Infect Dis Clin Pract (Baltim Md); 2015 Jan; 23(1):39-43. PubMed ID: 25574117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults.
    Welte T; Kantecki M; Stone GG; Hammond J
    Int J Antimicrob Agents; 2019 Oct; 54(4):410-422. PubMed ID: 31404620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume.
    Edeki T; Kujacic M; Broadhurst H; Li J; Sunzel M
    Br J Clin Pharmacol; 2014 Dec; 78(6):1291-7. PubMed ID: 25041494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience.
    Johnson LB; Ramani A; Guervil DJ
    BMC Infect Dis; 2019 Feb; 19(1):183. PubMed ID: 30791894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials.
    Corey GR; Wilcox MH; Gonzalez J; Jandourek A; Wilson DJ; Friedland HD; Das S; Iaconis J; Dryden M
    Int J Antimicrob Agents; 2019 Jun; 53(6):830-837. PubMed ID: 30716446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
    Kaye KS; Udeani G; Cole P; Friedland HD
    Hosp Pract (1995); 2015; 43(3):144-9. PubMed ID: 25956849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Vecuronium Quality Using Near-Infrared Spectrometry.
    Isaacs JT; Almeter PJ; Hunter AN; Lyman TA; Zapata SP; Henderson BS; Larkin SA; Long LM; Bossle MN; Bhaktawara SA; Warren MF; Lozier AM; Melson JD; Fraley SR; Relucio EHL; Felix MA; Reynolds JW; Naseman RW; Platt TL; Lodder RA
    Contact Context; 2023; 2023():. PubMed ID: 38187821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.
    Korczowski B; Antadze T; Giorgobiani M; Stryjewski ME; Jandourek A; Smith A; O'Neal T; Bradley JS
    Pediatr Infect Dis J; 2016 Aug; 35(8):e239-47. PubMed ID: 27164462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia.
    Rank DR; Friedland HD; Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii53-9. PubMed ID: 21482570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
    Cannavino CR; Nemeth A; Korczowski B; Bradley JS; O'Neal T; Jandourek A; Friedland HD; Kaplan SL
    Pediatr Infect Dis J; 2016 Jul; 35(7):752-9. PubMed ID: 27093162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corrado ML
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5-Minute Infusion.
    Riccobene TA; Carrothers TJ; Knebel W; Raber S; Chan PLS
    Clin Pharmacol Drug Dev; 2021 Apr; 10(4):420-427. PubMed ID: 33465279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
    Singh BN; Dedhiya MG; DiNunzio J; Chan P; Kupiec TC; Trissel LA; Laudano JB
    Am J Health Syst Pharm; 2011 Nov; 68(22):2163-9. PubMed ID: 22058102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
    Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
    Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit.
    Maggiore C; Vazquez JA; Guervil DJ; Ramani A; Jandourek A; Cole P; Friedland HD
    Ther Clin Risk Manag; 2015; 11():557-63. PubMed ID: 25897240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
    Scott LJ
    Drugs; 2016 Nov; 76(17):1659-1674. PubMed ID: 27766567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
    Huang X; Beresford E; Lodise T; Friedland HD
    Am J Health Syst Pharm; 2013 Jun; 70(12):1057-64. PubMed ID: 23719884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
    Cheng K; Pypstra R; Yan JL; Hammond J
    J Antimicrob Chemother; 2019 Apr; 74(4):1086-1091. PubMed ID: 30597021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Underlying Comorbidities on Outcomes of Patients Treated with Ceftaroline Fosamil for Complicated Skin and Soft Tissue Infections: Pooled Results from Three Phase III Randomized Clinical Trials.
    Wilcox M; Yan JL; Gonzalez PL; Dryden M; Stone GG; Kantecki M
    Infect Dis Ther; 2022 Feb; 11(1):217-230. PubMed ID: 34741280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.
    Dryden M; Zhang Y; Wilson D; Iaconis JP; Gonzalez J
    J Antimicrob Chemother; 2016 Dec; 71(12):3575-3584. PubMed ID: 27585969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.